Neogen & Gencove bring whole genome sequencing to cattle breeders

Developer and marketer of food and animal safety products, Neogen Corporation, and genome sequencing analysis software company, Gencove, will launch a solution for whole genome sequencing and SNP analysis that is targeted. The product, InfiniSEEK, is intended to help cattle breeders sequence herds in a cost-effective way. 

"Neogen offers innovative, high quality, value-added genomic technologies to the agrigenomics industry," said Dr. Jason Lilly, vice president of international business at Neogen. "With the launch of InfiniSEEK, our customers now have a data-rich, cost-efficient way to get genome-wide sequence data, specific genetic traits, and parentage markers simultaneously with excellent accuracy to characterize cattle across the world. We are excited to add this new solution to Neogen's portfolio."

The technology is able to decode DNA at shallow depth using the proprietary ability of Gencove’s software as a service (SaaS). The “low pass” sequencing of the cattle’s whole-genome analyses the DNA and genotypes based on the user’s interest. 

"Gencove developed a process that simultaneously yields low-pass whole genome sequencing and high coverage genotyping at pre-selected loci in a single molecular reaction," said Dr. Joseph Pickrell, co-founder and chief executive officer of Gencove. "InfiniSEEK is Neogen's first commercial product built on the Gencove software and analysis platform, and we are thrilled it will be deployed through Neogen's best in class genomics offering services.”

InfiniSEEK’s low pass sequencing has been tested at 99% comparable to deep sequencing. The technology is designed to allow the user to evaluate more than 400 diseases and genetic traits in bovines.

  • Please enter a comment

Name *
Email address *
Comment *

* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.

I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies

More news

Zoetis is Redefining the Feline Veterinary Experience with the Commercial Launch of Bonqat® (pregabalin oral solution) in the U.S.


Spatio-temporal patterns of tick-borne disease diagnoses in Indiana, USA (2009–2018)


Abdominal ultrasonographic findings of cats with feline infectious peritonitis: an update


Pseudohyperkalemia in horses with rhabdomyolysis reported by an enzymatic chemistry analyzer


Retrospective evaluation of prognosis and survival with various immunosuppressants in 82 dogs diagnosed with meningoencephalitis of unknown etiology (2010-2021).




News of interest


Copyright © 2024 - All Rights Reserved
ISSN 2768-198X